Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
LGND
Market Cap$1.53B
Close$
$27.04
68.6% downside
Current Fair Value
68.6% downsideOvervalued by 68.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.53 Billion |
|---|---|
| Enterprise Value | $1.22 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $5.41 |
| Beta | 0.96 |
| Outstanding Shares | 18,000,000 |
| Avg 30 Day Volume | 163,988 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 15.88 |
|---|---|
| PEG | 15.08 |
| Price to Sales | 14.34 |
| Price to Book Ratio | 1.96 |
| Enterprise Value to Revenue | 10.31 |
| Enterprise Value to EBIT | 17.46 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Ligand Pharmaceuticals, Inc.
CEO: John Higgins